Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder

Expert Review of Neurotherapeutics

Volumn 5, Issue 4, 2005, Pages 437-441

  McGough, James J ^a   Pataki, Caroly S ^b   Suddath, Robert ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Attention deficit hyperactivity disorder; Dexmethylphenidate; Focalin XR ; Pharmacotherapy stimulants

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ANOREXIA; ATTENTION DEFICIT DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE COST; HUMAN; INSOMNIA; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SLEEP DISORDER; SUSTAINED RELEASE PREPARATION;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CAPSULES; DELAYED-ACTION PREPARATIONS; HUMANS; METHYLPHENIDATE;

EID: 22544441871     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.4.437     Document Type: Review

References (33)

1. Faraone SV, Sergeant JA, Gilberg C et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2, 104-113 (2003). Recent meta-analysis of worldwide attention deficit hyperactivity disorder prevalence.
2. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition. Text Revision (DSM-IV-TR). American Psychiatric Press, WA, USA (2000).
3. Laufer MW, Denhoff E. Hyperkinetic behavior syndrome in children. J. Pediatr. 50, 463-474 (1957).
4. Faraone SV, Biederman J, Spencer T et al. Attention-deficit/hyperactivity disorder in adults: an overview. Biol. Psychiatry 48, 9-20 (2000).
5. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Comp. Psychiatry 37, 393-401 (1996).
6. Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers; implications for clinical diagnosis. J. Atten. Disorders 1, 147-161 (1996).
7. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J. Abnorm. Psychol. 111, 279-289 (2002).
8. Kessler RC. Prevalence of adult ADHD in the United States; results from the national comorbidity survey replication. Proceedings of the 157th Annual Meeting of the American Psychiatric Association. NY, USA (2004).
9. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Ann. Rev. Med. 53, 113-131 (2002).
10. American Academy of Pediatrics. Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 108, 1033-1044 (2001).
11. Greenhill LL, Halperin JM, Abikoff H. Stimulant medication. J. Am. Acad. Child Adolesc. Psychiatry 38, 503-512 (1999).
12. Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit/hyperactivity disorder; therapeutic potential. CNS Drug 18, 1011-1030 (2004). Recent review of new attention deficit hyperactivity disorder medications.
13. Pataki CS, Feinberg DT, McGough JJ. New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Emerg. Drugs 9, 293-302 (2004). Recent review of new attention deficit hyperactivity disorder medications.
14. Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs 62, 2251-2259 (2002).
15. Wigal S, Swanson JM, Feifel D et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 43, 1406-1414 (2004).
16. Weiss M, Wasdell M, Patin J. A post hoc analysis of d-threo- methylphenidate hydrochloride (Focalin®) versus d,l-threo-methylphenidate hydrochloride (Ritalin®). J. Am. Acad. Child Adolesc. Psychiatry 43, 1415-1421 (2004).
17. Quinn D, Wigal S, Swanson J et al. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 43, 1422-1429 (2004).
18. Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: methylphenidate formulations. Pharmacotherapy 23, 1281-1299 (2003). Review of methylphenidate formulations for attention deficit hyperactivity disorder.
19. Volkow ND, Wang GJ, Fowler JS et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155, 1325-1331 (1998).
20. Volkow ND, Wang GJ, Fowler JS et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine; therapeutic mechanisms. Synapse 48, 181-187 (2002).
21. Ruskin DN, Berstrom DA, Shenker A, Freeman LE, Black D, Walters JR. Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action. Biol. Psychiatry 49, 340-350 (2001).
22. Volkow ND, Wang GJ, Fowler JS et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am. J. Psychiatry 161, 1173-1180 (2004).
23. Sheldon RA. Chirotechnology: Industrial Synthesis of Optimally Active Compounds. Marcel Dekker, NY, USA (1993).
24. Thall E. When drug molecules look in the mirror. J. Chem. Educ. 73, 481-484 (1996).
25. Hutt AJ, Tan SC. Drug chirality and its significance. Drugs 52(Suppl. 5), 1-12 (1996).
26. Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacol. 160, 92-98 (2002).
27. Teo SK, Stirling DI, Thomas SD, Khetani VD. Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats. Pharmacol. Biochem. Behav. 74, 747-754 (2003).
28. Aoyama T, Kotaki H, Sawada Y, Iga T. Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine re-uptake sites. Pharmaceutical Res. 11, 407-411 (1994).
29. Ding YS, Fowler JS, Volkow ND et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacol. 131, 71-78 (1997).
30. Ding YS, Gatley SJ, Panayotis K et al. Brain kinetics of methylphenidate (Ritalin®) enantiomers after oral administration. Synapse 53, 168-175 (2004).
31. Lopez F, Muniz R, Pestreich L, Liu F, Jiang H, Agoropoulou C. Extended-release dexmethylphenidate: efficacy and safety in children with attention-deficit/hyperactivity disorder. J. Dev. Behavior. Ped. 25, 379 (2004). Placebo-controlled, double-blind study of dexmetylphenidate extended release in children.
32. Silva R, Muniz R, Pestreich L et al. Efficacy and safety of extended-release dexmethylphenidate in children with ADHD. Proceedings of the 45th Annual NCDEU Meeting. FL, USA. (2005).
33. Spencer T, Adler L, McGough J. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Proceedings of the 157th Annual Meeting of the American Psychiatric Association. NY, USA (2004). Placebo-controlled, double-blind study of dexmetylphenidate extended release in attention deficit hyperactivity disorder adults.